Parkinson's disease (PD) is regarded as a
movement disorder mainly affecting the elderly population and occurs due to progressive loss of dopaminergic (DAergic) neurons in nigrostriatal pathway. Patients suffer from non-motor symptoms (NMS) such as depression, anxiety,
fatigue and
sleep disorders, which are not well focussed in PD research. Depression in PD is a predominant /complex symptom and its pathology lies exterior to the nigrostriatal system. The main aim of this study is to explore the causative or progressive effect of chronic mild stress (CMS), a paradigm developed as an animal model of depression in
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (25 mg/kg. body wt.) with
probenecid (250 mg/kg, s.c.) (
MPTP/p) induced mice model of PD. After ten i.p.
injections (once in 3.5 days for 5 weeks) of
MPTP/p or exposure to CMS for 4 weeks, the behavioural (motor and non-motor) impairments, levels and expressions of
dopamine (DA),
serotonin (5-HT), DAergic markers such as
tyrosine hydroxylase (TH),
dopamine transporter (DAT), vesicular monoamine transporters-2 (VMAT 2) and α-
synuclein in nigrostriatal (striatum (ST) and substantia nigra (SN)) and extra-nigrostriatal (hippocampus, cortex and cerebellum) tissues were analysed. Significantly decreased DA and
5-HT levels, TH, DAT and VMAT 2 expressions and increased motor deficits,
anhedonia-like behaviour and α-
synuclein expression were found in
MPTP/p treated mice. Pre and/or post exposure of CMS to
MPTP/p mice further enhanced the
MPTP/p induced DA and
5-HT depletion, behaviour abnormalities and
protein expressions. Our results could strongly confirm that the exposure of stress after
MPTP/p
injections worsens the symptoms and neurochemicals status of PD.